COMMUNIQUÉS West-GlobeNewswire

Guardant Health Announces Pricing of Initial Public Offering
04/10/2018
REDWOOD CITY, Calif., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq:GH) today announced the pricing of its initial public offering of 12,500,000 shares of common stock at a public offering price of $19 [...]
Amedisys Extends Employment Agreement with CEO Paul Kusserow
03/10/2018
On Heels of Company Turnaround, Will Stay On For Three More Years BATON ROUGE, La., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED), America’s leading independent home health, hospice and personal care [...]
Spring Bank Announces Inarigivir Data Presentations at AASLD Conference
03/10/2018
HOPKINTON, Mass., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, [...]
ICC Labs Obtains Interim Order for Arrangement With Aurora Cannabis
03/10/2018
VANCOUVER, British Columbia, Oct. 03, 2018 (GLOBE NEWSWIRE) -- ICC Labs Inc. (the Company or ICC Labs ) (TSX-V: ICC) is pleased to announce that it has obtained an interim order of the Supreme Court of British Columbia [...]
KemPharm to Host KOL Investor Event Focused on the ADHD Treatment Landscape
03/10/2018
Event to be Webcast Live on Thursday, October 11, 2018, at 8:30 a.m. ET CORALVILLE, Iowa, Oct. 03, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and [...]
BioPorto receives communication from FDA regarding The NGAL Test™
03/10/2018
October 3, 2018 Announcement no. 17 BioPorto receives communication from FDA regarding The NGAL Test™ BioPorto A/S (“BioPorto”) announces today that the company has received communication from the U.S. Food and Drug [...]
Retrophin to Highlight Fosmetpantotenate Program for PKAN at Upcoming Medical Congresses
03/10/2018
SAN DIEGO, Oct. 03, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that presentations highlighting the design of the ongoing pivotal Phase 3 FORT Study of fosmetpantotenate for the treatment of [...]
Acasti Pharma Announces Public Equity Offering
03/10/2018
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE U.S. LAVAL, Quebec, Oct. 03, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ: ACST) (TSXV: ACST) (the “ Company ” or “ Acasti ”) is pleased [...]
Acasti Pharma Announces Proposed Underwritten Public Offering of Common Shares
03/10/2018
MONTRÉAL, Oct. 03, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate [...]
Corvus Pharmaceuticals Announces Publication of Preclinical Results Highlighting Antitumor Activity of CPI-444 in Multiple Tumor Models both as Monotherapy and in Combination Studies
03/10/2018
As Combination, CPI-444 Showed Elimination of Tumors in 90% of Treated Mice and Restoration of Immune Response in Mice with Tumors Resistant to Therapy with anti-PD-1 and anti-CTLA-4 BURLINGAME, Calif., Oct. 03, 2018 ( [...]
Paratek Pharmaceuticals, Inc. to Host Investor Day on October 23, 2018
03/10/2018
BOSTON, Oct. 03, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline [...]
Galapagos increases share capital through warrant exercises
03/10/2018
Mechelen, Belgium; 3 October 2018, 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from warrant exercises. Galapagos issued 135,485 new ordinary [...]
LaSanta Botanicals Announces Closing of $6.4 Million Financing
03/10/2018
CALGARY, Alberta, Oct. 03, 2018 (GLOBE NEWSWIRE) -- LaSanta Botanicals Ltd. (the “Company” or “LaSanta“) is pleased to announce that it has completed a non-brokered private placement offering of 10.7 million units (“ [...]
FDA Grants Orphan Drug Designation to Eidos Therapeutics’ Product Candidate, AG10, for Treatment of Transthyretin Amyloidosis
03/10/2018
SAN FRANCISCO, Oct. 03, 2018 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by [...]
Esperite N.V. (ESP): Sale by Esperite of stake in Cryo-Save South Africa cancelled
03/10/2018
Amsterdam, The Netherlands - 3 October 2018 Esperite N.V. (Euronext: ESP, the "Company" or "Esperite") today announced that the sale agreement between Esperite and Go-Life Healthcare Limited ("Go-Life Healthcare") as [...]
EssilorLuxottica:Disclosure of Share Capital and Voting Rights Outstanding as of October 2, 2018
03/10/2018
Disclosure of Share Capital and Voting Rights Outstanding as of October 2, 2018 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des [...]
EssilorLuxottica : Nombre total de droits de vote et d'actions composant le capital social au 2 octobre 2018
03/10/2018
Nombre total de droits de vote et d'actions composant le capital social au 2 octobre 2018 (Conformément à l'article L.233-8 II du Code de Commerce et aux articles 221-1 et 223-16 du Règlement Général de l'AMF) Charenton [...]
VALNEVA : Declaration d'actions et de droits de vote - septembre 2018
03/10/2018
VALNEVA Déclaration d'actions et de droits de vote - SEPTEMBRE 2018 Dénomination sociale : VALNEVA Adresse du siège social : 6 rue Alain Bombard, 44800 Saint-Herblain Marché réglementé Euronext Paris de Nyse Euronext - [...]
Nymox Reports Safety Benefits of Fexapotide Treatments for Prostate Cancer and Benign Prostatic Hyperplasia
03/10/2018
Excellent Safety Record Reinforced With Short-Term and Long-Term Safety Results of Repeated Injections of Fexapotide in 344 Patients Given Repeated Injections and Followed For 7 Years in 2 U.S. Trials HASBROUCK HEIGHTS [...]

Pages